论文部分内容阅读
目的:探讨新辅助化疗对局部晚期非小细胞肺癌患者术后生存质量的影响。方法:选取2011年5月至2012年5月于本院胸腔外科接受治疗的ⅢA~ⅢB期非小细胞肺癌患者240例并将其随机分成2组,即新辅助化疗组(A组)和单纯手术组(B组),每组120例。A组患者在临床确诊后接受2个周期的新辅助化疗,化疗结束2~3周后接受手术治疗;对照组患者临床确诊后直接行手术治疗。术后,两组患者均给予4周期常规放化疗。采用QLQ-C30量表对两组患者术前与术后第1、3、6个月的生存质量进行评估,并比较两组患者生存质量评分的差异。结果:术后1、3、6个月时,两组患者的各项功能分值均较术前显著升高(P<0.05);术后第3、6个月,患者的总体健康状况得分较术前显著升高(P<0.05);术后1个月时,A组患者的呼吸困难评分较术前明显增加(P<0.05),术后第3个月后,该分值与术前比较无显著性差异;术后第1、3个月时,两组患者的疼痛评分均较术前明显升高(P<0.05),但第6个月时,该评分与术前无显著性差异;术后第6个月时,两组患者的疲乏得分较术前明显降低(P<0.05);术后第1、3、6个月时,两组患者的经济困难评分明显较术前升高(P<0.05)。术后1、3、6个月时,A组患者的总体状况得分均显著高于B组(P<0.05),呼吸困难评分和疲乏评分明显低于B组(P<0.05),经济困难评分均显著高于B组(P<0.05)。结论:新辅助化疗可以提高局部晚期非小细胞肺癌患者术后半年内的生存质量。
Objective: To investigate the effect of neoadjuvant chemotherapy on postoperative quality of life in patients with locally advanced non-small cell lung cancer. Methods: A total of 240 patients with stage ⅢA-ⅢB non-small cell lung cancer who underwent thoracic surgery in our hospital from May 2011 to May 2012 were randomly divided into two groups: Neoadjuvant chemotherapy group (A group) and simplex Surgery group (B group), each group of 120 cases. Patients in group A received 2 cycles of neoadjuvant chemotherapy after clinical diagnosis. Patients in control group received surgical treatment 2 to 3 weeks after the end of chemotherapy. Patients in control group were treated directly by clinical diagnosis. After surgery, both groups were given 4 cycles of conventional radiotherapy and chemotherapy. The QLQ-C30 scale was used to evaluate the quality of life of the two groups before and 1, 3 and 6 months after operation. The difference of quality of life between the two groups was also compared. Results: At 1, 3, and 6 months after operation, the functional scores of both groups were significantly higher than those before operation (P <0.05). At 3 and 6 months after operation, the scores of patients’ overall health status (P0.05) .At 1 month after operation, the score of dyspnea in group A was significantly higher than that before operation (P0.05) .After 3 months, the score and operation There was no significant difference between the two groups at the first and third month after operation (P 0.05), but no significant difference between the two groups was found at the 6th month (P <0.05). At the 6th month after operation, the fatigue scores of the two groups were significantly lower than those before the operation (P <0.05). At 1, 3 and 6 months after operation, the economic difficulty scores of the two groups were significantly higher than those of the two groups Before rising (P <0.05). At 1, 3 and 6 months after operation, the overall score of patients in group A was significantly higher than that in group B (P <0.05), and the scores of dyspnea and fatigue were significantly lower than those in group B (P <0.05) Were significantly higher than the B group (P <0.05). Conclusion: Neoadjuvant chemotherapy can improve the quality of life of patients with locally advanced non-small cell lung cancer within six months after operation.